the low concentrations of circulating hyaluronate. However, the recent development of a radioassay for hyaluronate14 has allowed its determination in small tissue samples and in various body fluidsaqueous humour,15 amniotic fluid, 16 and serum. '7 In this study we have measured the serum levels of hyaluronate in patients with rheumatoid arthritis and pelvospondylitis to test the possibility that inflammatory connective tissue diseases are associated with increased serum levels of hyaluronic acid.
Patients and methods
Serum samples were collected from 37 patients with rheumatoid arthritis. All patients met the criteria of the American Rheumatism Association for definite or classic disease.'8 Twenty-nine were female. The mean age was 49 years; the mean duration of the disease seven years. The patients had been treated with various non-steroidal anti-inflammatory drugs, which were withdrawn 3-4 days prior to blood sampling. The blood samples were collected between 7.30 and 8.00 am. 83 Serum samples were also collected from 18 patients with ankylosing spondylitis. All patients conformed to the New York criteria19 and they were all HLA-B27 positive. Fourteen were male. The mean age was 42 years, and the mean duration of disease 14 years. The patients were treated with non-steroidal anti-inflammatory drugs, but 3-4 days before blood collection therapy was withdrawn. Blood sampling was performed under the above mentioned conditions. None of the patients had signs or symptoms of active disease in the peripheral joints. The control group consisted of healthy blood donors.
Hyaluronate was determined according to the principles previously outlined'4 and recently adapted for measurement in serum samples. ' The inflammatory activity defined by ESR and certain acute-phase reactants and the serum levels of IgG was similar in the two patient groups (Table 1) . In patients with rheumatoid arthritis we found significant correlations of hyaluronate serum levels with orosmucoid (r=05, p<001) (Fig. 2) , haptoglobin (r=0-40, p<005), and a1-antitrypsin (r=061, p<0001) concentrations, and with ESR (r=034, p<0-05). The duration of disease was not related to the hyaluronate concentrations.
HYALURONATE CONCENTRATIONS AND IMMUNE COMPLEXES
We found no differences in hyaluronate concentrations of rheumatoid arthritis patients with or without circulating immune complexes measured by different techniques (Table 2) . Neither did the RF titre influence the hyaluronate concentrations (data not shown). This study has shown that the serum hyaluronate concentration is high in rheumatoid arthritis but not in ankylosing spondylitis, although the biochemical evidence of disease activity was equally raised in both patient groups. The practical clinical value of hyaluronate determinations in rheumatoid arthritis is at present uncertain. Prospective studies are in progress with the object of assessing the relation of hyaluronate to the extent of articular and extraarticular manifestations in rheumatic diseases and the long-term influence on hyaluronate serum levels of different treatments. Whether the in-vitro observations on the effects of hyaluronate on lymphocytes,30 31 monocytes/macrophages, 32-34 and neutrophils35 36 are relevant to in-vivo situation has not yet been settled. However, the possibility of a modulatory role of hyaluronic acid in inflammation is another fascinating aspect of this polysaccharide which also merits further investigation.
